Syncromune®

Drug/device combination development might be the ultimate #biotech business challenge. Convincing investors and regulators to back and approve never-before-seen products takes a special blend of grit and optimism. On this week's episode of the #businessofbiotech podcast, Syncromune® President & CEO Eamonn Hobbs, a guy who's cleared the bar before, tells tales of success in a daunting arena and shares on his company's SYNC-T platform therapy for metastatic solid tumor #cancer. Watch here https://lnkd.in/eur__HP, or listen and subscribe anywhere you get your podcasts. Bioprocess Online Life Science Connect

Hear more about Syncromune and our lead candidate SV-102 (recently fast-tracked by the FDA) from CEO Eamonn Hobbs on this week’s #BusinessOfBiotech. https://bit.ly/3VHXVuw

We are pleased to announce that in addition to our recent FDA IND clearance of SYNC-T SV-102 for mCRPC, the FDA has also granted Syncromune fast track designation for the therapy. This program may provide benefits such as more frequent engagement with the FDA, eligibility for accelerated approval, and priority review. You can read more about fast track designation and Syncromune in the press release below or at www.syncromune.com

Syncromune is excited to announce that we received FDA clearance of our IND application for SYNC-T SV-102! Visit us at booth #10047 at the 2024 American Society of Clinical Oncology (ASCO) meeting to learn more about our upcoming LEGION-100 Phase 1b trial for mCRPC. Read the full press release here: https://lnkd.in/egJew-sm.

Syncromune will be in Chicago from June 1-June 3 for the 2024 American Society of Clinical Oncology (ASCO) meeting! Visit us at booth #10047 to learn more about SYNC-T™, our in-situ solid tumor therapy platform and recent positive Phase 1 data for mCRPC. More details on where to find our booth here: https://lnkd.in/eZ-fEmZx #ASCO24

Last month at the American Association for Cancer Research Annual Meeting, President and CEO of Lankenau Institute for Medical Research (LIMR) George Prendergast, Ph.D., spoke with the Video Journal of Oncology (VJOncology) about the combination multi-target SYNC-T Therapy. In the interview, Dr. Prendergast discusses preclinical modeling work being done at LIMR, including how SYNC-T works and its potential advantages. Learn more about #SYNCT in the series of video interviews here: https://bit.ly/44lt2QB

In this article titled, “AACR 2024: What Cancer Researchers are Talking About,” BioSpace shares some of the hottest topics coming out of the conference, including data from the Phase 1 trial evaluating Syncromune’s SYNC-T therapy in patients with metastatic prostate cancer. Learn more by visiting the article, here: https://bit.ly/3JqlulT

#ICYMI, BioWorld covered the results from the Phase 1 study and late breaking presentation at this year’s AACR meeting in an article titled, “AACR 24: Freezing, of all things, is one way to heat cold tumors.”

#ICYMI Positive phase 1 data from the SYNC-T SV-102 trial was recently presented at #AACR24! Dive into the details and join the conversation surrounding these promising results. Click below to catch up on the latest buzz! https://bit.ly/43TPK1Z